Aspen Pharmacare Holdings Limited (JSE:APN) Director Jeremy Yaseniuk sold 50,000 shares of Aspen Pharmacare stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $0.49, for a total transaction of $24,500.00.
Jeremy Yaseniuk also recently made the following trade(s):
- On Monday, January 29th, Jeremy Yaseniuk sold 25,000 shares of Aspen Pharmacare stock. The shares were sold at an average price of $0.51, for a total transaction of $12,750.00.
- On Friday, January 26th, Jeremy Yaseniuk bought 10,000 shares of Aspen Pharmacare stock. The shares were purchased at an average price of $0.41 per share, for a total transaction of $4,100.00.
Aspen Pharmacare Holdings Limited (APN) opened at $25,502.00 on Wednesday. Aspen Pharmacare Holdings Limited has a one year low of $23,498.00 and a one year high of $32,750.00. The firm has a market cap of $116,400.00 and a price-to-earnings ratio of 2,283.08.
TRADEMARK VIOLATION NOTICE: “Aspen Pharmacare Holdings Limited (APN) Director Sells 50,000 Shares” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://stocknewstimes.com/2018/02/14/aspen-pharmacare-holdings-limited-apn-director-jeremy-yaseniuk-sells-50000-shares-of-stock.html.
Aspen Pharmacare Holdings Limited is a South Africa-based supplier and manufacturer of branded and generic pharmaceutical products, as well as infant nutritional and consumer healthcare products. The Company’s segments include International, South Africa, Asia Pacific and Sub-Saharan Africa (SSA). Its International business includes operating subsidiaries in Europe, Commonwealth of Independent States (CIS), Latin America, the Middle East and North Africa, Canada, as well as Mauritius-based Aspen Global Incorporated.
Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.